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Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene
expression involved in normal mesodermal and endodermal developments. A close association between rs4430796
polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the
current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients.
Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed
on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients’ genotype on overall survival
and progression free survival were our main outcome measures.
Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003)
among genotypes. At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage,
and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796
polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus
chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also
detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on pro-
gression free survival.
Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a
potential effect on tumor chemo-sensitivity.
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Several genes in the sex steroid hormone metabolism
pathway have been investigated for polymorphic variants
that predispose to endometrial cancer (EC). Single nu-
cleotide polymorphisms (SNPs) in these genes are asso-
ciated with EC risk [1]. For example, CYP19A1
(aromatase) genetic variation influenced susceptibility to
EC, particularly among older and obese patients [1].
However, very little part of the genetic risk can be explained
by these SNPs.
Hepatocyte nuclear factor-1beta (HNF1B) (formerly
known as TCF2) gene encodes for a transcription factor
that regulates gene expression involved in normal mesoder-
mal and endodermal developments [2]. HNF1B protein* Correspondence: dariomandato@virgilio.it
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unless otherwise stated.exists in three isoforms: isoforms A and B, which act as
transcriptional activators, and isoform C, which acts as a
transcriptional repressor [2]. HNF1B regulates gene expres-
sion necessary for normal mesodermal and endodermal de-
velopment, and is expressed in numerous tissues. The loss
of function in HNF1B has been reported in genetic syn-
dromes such as Mayer-Rokitansky-Kuster-Hauser [3-5] and
Prune Belly syndrome [6]. In addition, the oncogenic role
of HNF1B has been reported in several cancers such as
renal, colorectal, gastric, pancreatic, and ovarian cancer.
HNF1B overexpression has been reported to be a bio-
marker of ovarian clear-cell carcinoma (CCC), of its prob-
able precursor, endometriosis and of EC [6-8]. HNF1B can
be considered an oncogene [6-8] and plays a role in the ori-
gin of CCC not only in ovary but also in uterus [9,10].
Moreover, HNF1B expression was also investigated to clas-
sify the several EC histotypes [11].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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SNP (G allele of rs4430796) in HNF1B associated with
decreased EC risk in women of European background
[12]. In 2012, the Population Architecture using Genom-
ics and Epidemiology (PAGE) study [13] confirmed that
HNF1B SNP was associated with a decreased risk of EC
in the populations of two independent studies [14-16].
The associations were observed across multiple racial/
ethnic groups and similar associations were seen for
both type I and type II ECs and across all categories of
body mass index (BMI), parity, oral contraceptives use,
menopausal hormone use, and smoking status [17].
More recently, in order to search additional common
genetic variants, a further GWAS was conducted in EC
populations participating in studies of the Epidemiology
of Endometrial Cancer Consortium [18]. Previous data
on G allele of rs4430796 were confirmed and no new
SNPs were found [18]. Moreover, analysis of several
lymphocyte-derived gene expression datasets indicated a
significant association between rs4430796 genotype and
HNF1B expression [12]. HNF1B expression may regulate
the process of tumorigenesis [10] and the biological be-
havior of EC such as chemoresistance.
Despite several studies reported a relationship be-
tween rs4430796 and EC risk, no data is available in
literature about the relationship between rs4430796
and EC prognosis. Based on these considerations, the
purpose of the current experimental study was to test
hypothesis that rs4430796 polymorphism influences the
prognosis in EC patients.
Methods
Ethics
The Provincial Ethical Committee of Reggio Emilia ap-
proved the study design and all patients provided written
informed consent to use personal non-sensitive data at
hospital admission.
Study protocol
The study design followed the Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE)
statement [19]. Clinical charts of EC patients treated and
followed at the IRCCS-Santa Maria Nuova Hospital of
Reggio Emilia (Italy) from 1997 to 2010 were checked
for inclusion and exclusion criteria.
Tissue samples of the included patients were retrieved,
prepared, and stored in the tissue storage system of the
Department of Pathology. Genomic DNA extraction and
purification, and rs4430796 genotyping was performed
in the Laboratory of Molecular Biology.
Clinical, pathological and genetic data were recorded in
an electronic separate, anonymous, password-protected
database. All relevant data were extrapolated and used for
final analysis.The overall survival (OS) and the progression free sur-
vival (PFS) were considered the two main outcome mea-
sures to assess EC prognosis. The OS was computed as
the time period from the date of surgery to either the
date of death or last follow up, whichever occurred first,
and the PFS was computed as the disease-free period
from the date of surgery to the date of relapse or last fol-
low up, whichever occurred first.
Population
Patients with histological diagnosis of EC who received
upfront surgery treatment were electively included in
the protocol study.
Exclusion criteria were: inadequate EC treatment ac-
cording to internal and international guidelines [20,21],
neoadjuvant chemotherapy performed before surgery, an
age less than 18 years, non-Caucasian ancestry, a follow-
up length shorter than 6 months, inadequate follow-up
according to internal guidelines, absence of written in-
formed consent, diagnosis of a previous or concurrent
cancer(s) and unavailable follow-up data.
An adequate treatment was considered as follows: total
extrafascial hysterectomy (TEH) with bilateral salpingo-
oophorectomy (BSO) was the standard staging procedure;
whereas radical hysterectomy (RH) was performed only in
stage II EC patients with gross cervical involvement; pelvic
with/without paraaortic lymph node dissection were per-
formed in case of Type II EC, myometrial invasion greater
than 50 percent, large tumor (>2 cm in diameter) or filling
the endometrial cavity; omentectomy, appendicectomy
(for mucinous cancers), peritoneal biopsies, and maximal
tumor debulking were always performed in case of type II
EC patients.
Vaginal brachytherapy alone was administered to
patients at stage IA G3 and IB G1 or G2 without
negative prognostic factors. External beam radiother-
apy plus vaginal brachytherapy was administered to
patients at stage IA G3 and IB G1 and G2 with nega-
tive prognostic factors, to patients at stage IB G3 and
to all patients at stage II, III and IV. Chemotherapy
was administered to patients at stage III C and IV. In
all cases, chemoradiotherapy consisted of paclitaxel
175 mg/m2 (P) and carboplatin AUC5 (C) on day 1
every three weeks, for a total of four to six cycles, and
it was followed by external pelvic radiation therapy
(1.8 Gy/d, d1-5) at a total dose of 45 Gy plus vaginal
brachytherapy (3 × 5 Gy) [20,22].
A follow-up was defined “adequate” in case of adher-
ence to the following schedule: type I EC at stage IA and
grading G1/G2 - physical and gynecological examin-
ation, and transvaginal ultrasound every 6 months for
the first 2 years, and then every 12 months for at least
3 years; type I EC at stage IB and/or any grade G3
tumour and any EC type II - physical and gynecological
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6 months for the first 5 years. Further investigations
such as abdominal ultrasound, chest X-ray, computed
tomography scan, and CA 125 serum level were per-
formed if clinically indicated.
Tissue samples, DNA extraction, sequencing and analysis
of rs4430796-SNP
The same pathologist (M.C.G.) with long-time expertise
in gynecological oncology reviewed all the histological
samples to confirm formally the diagnosis. Then, she cut
the formalin-fixed and paraffin-embedded tissue in order
to obtain 5 μm-thick slices of non-tumor tissue for
genomic test.
Two operators (E.F, B.C.) performed the genomic
DNA extraction and purification using the BiOstic® FFPE
Tissue DNA Isolation Kit (MoBio Laboratories, Inc.,
Carlsbad, CA, US) and quantification using Nanodrop
2000 (Thermo Fisher Scientific Inc., DE, US).
Rs4430796 genotyping was performed by LGC Gen-
omics / KBioscience (Hertfordshire, UK) using KASP™
genotyping assay, which employs a competitive allele-
specific protein chain reaction (PCR) (http://www.
Kbioscience.co.uk).
The minor and major alleles of rs4430796 SNP were
defined as A and G, respectively.
Statistical analysis
For statistical analysis, R-2.15.1 software was used.
Associations between rs4430796 and clinical and
pathological parameters were assessed by generalized
linear models. Survival curves were plotted using the
Kaplan–Meier method and analyzed using the log-
rank test. Cox regression hazard model was used for
multivariate analysis to assess the independent influ-
ence of rs4430796 SNP and other covariates on overall
survival and cancer recurrence.
Results were presented as hazard ratio (HR) and 95%
confidence interval (CI). To evaluate combined effects be-
tween polymorphism and clinical and pathological param-
eters, interaction hazard ratios (IHR) were calculated
fitting Cox model. IHR compared the observed HR due to
variables synergy to the expected HR obtained by multipli-
cation of single effect of each variable when the other one
is not involved (IHR =HR11/HR01*HR10). IHR = 1 indi-
cated no synergy between variables, IHR <1 expressed a
reduction of risk due to variables synergy, while IHR >1
denoted an increased risk.
Results
After patients careful selection for inclusion and exclu-
sion criteria, 191 EC patients were studied and included
in the final analysis.In all EC patients a complete resection of the disease
was obtained.
In Table 1 the main clinical and pathological data of
the studied population are summarized [23].
Total extrafascial hysterectomy was performed in 179 of
191 patients (93.7%), radical hyesterctomy was performed
in 12 of 191 patients (6.3%), salpingo-oophorectomy was
performed in 184 of 191 patients (96.3%), omentectomy
was performed in 35 of 191 patients (18.3%), appendicec-
tomy was performed in 9 of 191 patients (4.7%), pelvic
lymphadenectomy was performed in 129 of 191 patients
(67.5%), lombo-aortic lymphadenectomy was performed
in 15 of 191 patients (7.9%).
After a median follow-up time of 64 months (range, 7 to
151 months), a total of 18 patients died (18/191, 9.4%).
Twenty two patients (22/191, 11.5%) had a recurrence.
Sixteen of 18 dead patients (88.9%) had a recurrence.
Overall survival was 46 months (range, 7 to 136 months).
A allele frequency of rs4430796 SNP was 0.46. GG,
AG and AA genotypes were found in 57 (57/191, 29.8%),
91 (91/191, 47.6%) and 43 (43/191, 22.5%) patients, re-
spectively. That genotypic distribution of polymorphism
resulted in Hardy-Weinberg equilibrium (P = 0.56).
In Figure 1 is showed the estimate probability of OS ac-
cording to three rs4430796 SNP genotypes. A significant
(P = 0.003) difference among genotypes was observed, and
the worst OS was observed for GG genotyped patients.
Thus, further analyses were performed grouping AG and
AA genotypes (vs. GG genotype) assuming dominant ef-
fect of A allele.
No difference in any clinical and pathological data was
detected between GG and GA/AA stratified EC patients
(Table 1).
The effect of the main clinical and pathological
parameters on OS and PFS was tested using multivari-
ate Cox model (Table 2). In the model data were ad-
justed only for age since in the present study EC FIGO
grading could be applied only in a proportion of patients
and patients’ performance status were similar in all cases
since selected for “full surgery” and adjuvant therapy.
Analysis showed a highly significant effect (P = 0.003)
of rs4430796 polymorphism on OS while only a trend
(P = 0.090) towards significance was observed for SNP
effect on PFS. Between other parameters only FIGO
stage maintained a slightly significant effect on OS and
PFS after adjustment.
The effect of rs4430796 polymorphism on OS in EC
patients according to adjuvant therapy is showed in
Figure 2. No significant effect was detected in EC
patients who did not receive adjuvant therapy and in
those treated with radiotherapy (Figure 2). In EC
patients who received radiotherapy plus chemotherapy
a significant (P < 0.001) effect of rs4430796 polymorph-
ism on OS was detected. A significant (P = 0.014)
Table 1 Main clinical data in overall EC population and in EC patients categorized according to rs4430794 genotypes
Characteristic Patients (n.) rs4430796 P value
GG (n. %) GA/AA (n. %)
191 57 134
Age1 64.3 ± 10.6 64.9 ± 10.1 64.0 ± 10.8
Histological type
Type I 162 46 (28.4) 116 (71.6)
Type II2 29 11 (37.9) 18 (62.1) 0.304
Figo stage2
I 152 45 (29.6) 107 (70.4)
II 12 4 (33.3) 8 (66.7)
III 23 6 (26.1) 17 (73.9)
IV 4 2 (50.0) 2 (50.0) 0.820
Grading (for Type I)
G1 70 17 (24.3) 53 (75.7)
G2 63 18 (28.6) 45 (71.4)
G3 29 11 (37.9) 18 (62.1) 0.186
Myometrial invasion
<50% 100 30 (30.0) 70 (70.0)
>50% 91 27 (29.7) 64 (70.3) 0.960
Lymph node metastasis (129 lymphadenectomy)
No 113 34 (30.1) 79 (69.9)
Yes 16 4 (25.0) 12 (75.0) 0.677
Adjuvant treatment
None 119 36 (27.9) 83 (64.3)
Radiotherapy 42 12 (28.6) 30 (71.4)
Chemo-Radiotherapy 30 9 (30.0) 21 (70.0) 0.926
Radiotherapy (42 patients)
External beam therapy 2 1 (50.0) 1 (50.0)
Brachytherapy 21 6 (28.6) 15 (71.4)
Combined 19 5 (26.3) 14 (73.7) 0.615
1 Age (years) is shown as mean ± SD.
2 Staging and grading were done according to the 2009 International Federation of Gynecology and Obstetrics (FIGO) classifications [23]. Women treated before
2009 were restaged according to the 2009 FIGO classifications.
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chemo-radiotherapy was also observed (Figure 2). A
significantly (P < 0.001) worse OS was observed only in
subjects with GG genotype who received radio-
chemotherapy as adjuvant treatment (Figure 2).
In Figure 2, the estimate OS comparing different
rs4430796 SNP genotypes in EC patients classified ac-
cording to adjuvant therapy is showed. A significantly
(P < 0.001) worse OS was observed only in subjects with
GG genotype who received radio-chemotherapy as adju-
vant treatment (Figure 2).
Discussion
To our knowledge, this was the first study aimed to test
the hypothesis that rs4430796 influences the OS ofpatients with EC. Current retrospective cohort study
showed that the OS of EC patients varied significantly
according to rs4430796 genotypes and at multivariate
analysis rs4430796 SNP genotype resulted an independ-
ent risk factor for OS in EC patients. In particular, GG
genotyped patients showed the worst OS.
In order to explore this influence, our population was
studied according to adjuvant treatment. In EC patients
treated with post-surgical radio-chemotherapy, subjects
with GG genotype had a significant HR of 39.1 for death,
even if a wide CI was observed. Of note, a significant
interaction between rs4430796 polymorphism and treat-
ment was detected showing that the impact on OS is dif-
ferent from that expected from the sum of the individual
effects of the two variables. Those findings were not
Figure 1 Kaplan-Meier plot of estimate probability of overall survival in relation to three rs4430796 SNP genotypes.
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therapy and for those who received radiotherapy alone,
suggesting that rs4430796 polymorphism could play a
crucial role in tumor sensitivity to chemotherapy. To
this regard, no other study is available in literature and
our study was the first to suggest that A allele of
rs4430796 in EC patients undergoing chemo-
radiotherapy might reduce the risk of death by increas-
ing the response to therapy.
Well-known prognostic factors for EC include age,
race, stage, grade, ploidy, depth of invasion, tumor size,
receptor status, and cell type [24]. However, these mul-
tiple factors failed to give an accurate estimate of prog-
nosis, whereas some genetic variants, such as rs4430796,
may be in the next future a useful marker to predict,
alone or in combination, the prognosis of EC patients.
Although many studies have investigated HNF1B in
gynecological malignancies, such as CCC, showing its
relationship with tumor cell survival [25] and tumor-
associated thrombosis [6], few data are reported on itsrole in EC. A GWAS demonstrated that G allele of
rs4430796 is associated with decreased EC risk in
European population [12] and the PAGE study [13,14]
subsequently confirmed those findings in two independ-
ent studies. The associations were observed irrespec-
tively of several demographic, anthropometric,
hormonal, voluptuary patients’ characteristics [17].
Finally, a more recent GWAS [18] confirmed previous
finding [12] and no new SNPs were found. Recently,
HNF1B was found to be overexpressed in EC [9-11],
particularly in CC EC [26].
No data were found in literature explaining the role of
rs4430796 genotype on HNF1B function but some contra-
dictory studies supposed that rs4430796 polymorphism
could influence HNF1B gene expression [12,27-30].
Spurdle et al. [12] analyzed several lymphocyte-derived
gene expression datasets and identified significant associa-
tions between rs4430796 genotype and HNF1B expression
in individuals of European ancestry. In the same popula-
tion, a RNA sequencing experiment suggested that
Table 2 Effect of the main clinical and pathological parameters on overall survival and progression free survival using
multivariate Cox models
Overall survival Progression free survival
Multivariate Cox model Multivariate Cox model
Women Deaths HR (95%CI) P value* Relapses HR (95%CI) P value*
Histotype 191 18 22
Type I 162 9 1 13 1
Type II 29 9 2.3 (0.56-9.22) 0.254 9 1.6 (0.51-5.38) 0.406
Myometrial invasion
<50% 100 2 1 4 1
≥50% 91 16 4.4 (0.74-26.07) 0.104 18 3.2 (0.82-12.10) 0.094
FIGO stage
I 152 6 1 9 1
II 12 3 5.9 (1.00-34.54) 0.050 4 5.4 (1.21-23.94) 0.027
III 23 6 6.1 (1.08-34.54) 0.041 6 4.1 (0.75-22.66) 0.102
IV 4 3 7.64 (0.84-69.49) 0.071 3 9.5 (1.16-77.7) 0.036
Adjuvant treatment
None 119 6 1 10 1
Radiotherapy 42 3 0.37 (0.07-1.95) 0.239 2 0.20 (0.04-1.05) 0.057
Chemo-Radiotherapy 30 9 0.94 (0.16-5.58) 0.947 10 0.65 (0.13-3.18) 0.598
rs4430796
GG 57 11 1 10 1
AG + AA 134 7 0.18 (0.06-0.56) 0.003 12 0.46 (0.18-1.13) 0.090
CI = confidence interval, HR = hazard ratio. * P values were calculated with Log-rank test and express statistical differences in overall survival and progression
free survival.
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genotypes presented a trend of increase in read depth with
increasing number of G alleles [12].
Recent and not always concordant studies analyzed
the influence of HNF1B gene expression on chemosensi-
tivity in ovarian cancer [27,28,30]. In particular, some
studies, observing that ovarian CCC characterized by
HNF1B overexpression were often chemo-resistant, sug-
gested a possible effect of the level of HNF1B on chemo-
sensitivity. It was demonstrated that shRNA mediated
downregulation of HNF1B sensitizes ovarian cancer
cells to cisplatin- or paclitaxel-mediated cytotoxicity,
through inverse regulation of HSulf1 expression [27]. In
2014, an interesting mechanism of inhibition of cell
death by HNF1B transcription factor was also proposed
[28]. Specifically, it was demonstrated that chemoresis-
tance that characterizes CCC might be due to aberrant
retention of the G2 checkpoint of cell cycle induced by
HNF1B overexpression [28]. In addition, HNF1B might
induce this aberrant retention through the upregulation
of CHK1 kinase, a protein that plays a pivotal role in the
G2 checkpoint [28].
It was not possible for us to evaluate HNF1B gene ex-
pression in FFPE samples. The supposition of a potential
biological model will require further experiments but,based on published studies, we suppose that the correl-
ation that we observed between rs4430796 GG genotype
and reduced OS in patients treated with chemotherapy
could support the hypothesis that G allele reduces che-
mosensitivity through HNF1B overexpression. Identifica-
tion of EC patients candidate for chemotherapy with
rs4430796 GG genotype could be useful in the clinical
practice in the next future to schedule a different chemo-
therapy and/or the administration of a sensitization agent.
A recent study showed that the administration of CHK1
inhibitors to human cell line of CC EC treated with
bleomicin was followed by an increase cell death rate
[28]. Similarly, CHK1 inhibitors administration might
decrease the chemoresistance to several drugs [28].
However, new agents that enhance the chemosensitivity
should be investigated.
Unlike to HNF1B, ARID1A downexpression, mutation
or loss of function is associated with chemoresistance and
deep myometrial invasion in EC [31,32]. ARID1A is a
tumor suppressor gene. Inactivating mutations of
ARID1A and loss of its expression was found especially
in endometrium-derived tumors, including ovarian
CCC, ovarian endometrioid carcinomas and EC [33,34].
Both ARID1A and HNF1B play a role in the pathogen-
esis of ovarian CCC arose in endometriosis and both
Figure 2 Kaplan-Meier plot of estimate probability of overall survival comparing GG vs. AG + AA rs4430796 genotypes in EC patients
classified according to adjuvant treatment. Log-rank test P < 0.0001.
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Usually, ARID1A mutation is an early event in neoplas-
tic transformation and it is present both in carcinoma
and preneoplastic tissue whilst HNF1B is usually found
only in cancer tissue [8]. ARID1A mutations co-occur
with mutations of PTEN and PIK3CA. Furthermore, PI3K
pathway activity is regulated by ARID1A through phos-
phorylation of AKT [35]. Also AKT is involved in che-
moresistance of EC cells, particularly Akt2 and Akt3
isoforms are involved in cell chemoresistance independ-
ently of the drug used for treatment [36,37]. Both AKT
and HNF1B take part in the signaling pathway that regu-
lates insulin secretion in pancreatic beta cells and their
involvement in EC could suggest a possible role, not yet
investigated, of these genes in the regulation of tumor
cells glucose homeostasis [38,39] since abnormal glucosehomeostasis is a well-known risk factor for EC type 1.
However, despite a direct interaction between HNF1B
and ARID1A/AKT was not yet clarified, aforementioned
evidences suggest that a common pathway could be im-
plicated in the pathogenesis and biological behavior of
EC. Further studies need to elucidate these potential
interactions from a biological and clinical point of view.
Current study presents issues of strength and limita-
tion. The strength of our study regards the selection
of a very homogeneous population of EC patients who
received an upfront surgery with adequate treatment
and follow-up length. The centralization of treatment,
follow-up, and pathology review are further study
strengths that ensured a uniformity of treatment, sta-
ging procedures, post-treatment monitoring and
histological classification. Instead, in other available
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widely varied [40]. Furthermore, our study has also im-
portant limitations. In particular, it might be underpow-
ered because of the small cohort, and actual sample size
might not be sufficient to detect a synergistic effect in a
replicate study. However, despite the small sample size,
the genotype distribution in our population comply with
Hardy-Weinberg equilibrium indicating that identified
significant association can be considered representative
and not-biased by patients selection. Regarding to small
sample size of this study, we did not manage to recruit a
sufficient number of EC patients with advanced disease
to request chemo-radiotherapy because most EC is diag-
nosed at early stage, and chemo-radiotherapy is com-
monly delivered in less than 10% of subjects [20-22].
Chemo-radiotherapy is generally administered to EC pa-
tients with positive lymph nodes (stage III) or distant
metastases (stage IV) [20-22]. That population repre-
sents the 6-7% and 3% of EC patients, respectively of the
overall EC population. In addition, the rate of 5-year sur-
vival for stage I disease is approximately 80-90%, for
stage II, 70- 80%, and for stages III and IV, 20-60% [22].
Hence the mortality is also low.
Conclusions
Current preliminary study demonstrates that the
mortality of EC patients is significantly and independ-
ently influenced by rs4430796 polymorphism. This
effect is probably exerted through tumor chemo-
sensitivity. Further large multicenter studies need to
confirm our results and to assess whether rs4430796
polymorphism could predict adjuvant treatment effect-
iveness in EC patients.
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